Pivekimab sunirine approved for BPDCN: the CD123 story

On May 27, 2026 the FDA approved pivekimab sunirine-pvzy (Decnupaz, AbbVie), the first antibody-drug conjugate for blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare and aggressive blood cancer. It is a milestone for a disease that, until recently, had essentially no standard of care. It is also a clean illustration of why some targets get drugged with biologics and others with small molecules — and where the two strategies meet.

Why CD123, and why an antibody-drug conjugate

BPDCN arises from precursors of plasmacytoid dendritic cells, and its defining surface feature is uniform, high expression of CD123, the alpha chain of the interleukin-3 receptor. CD123 is a receptor on the cell surface, not an enzyme with a deep druggable pocket, so the practical way to hit it is to aim a targeting antibody at it rather than design a small molecule to plug an active site. That logic produced the first BPDCN drug, tagraxofusp (a CD123-IL3 fusion toxin), and now pivekimab sunirine, which takes the same address label and upgrades the warhead.

• Pivekimab sunirine — a high-affinity anti-CD123 antibody joined through a cleavable linker to an indolinobenzodiazepine pseudodimer payload that crosslinks DNA. The antibody delivers; the payload kills once internalized.
• Tagraxofusp — the prior CD123-directed agent, a diphtheria-toxin fusion, established that CD123 is a tractable address in BPDCN but carried capillary leak syndrome as a signature toxicity.

The CADENZA data

Approval rested on the single-arm CADENZA trial (NCT03386513). In treatment-naive BPDCN, roughly 70% of patients reached a complete response or clinical complete response after a median follow-up of about 21 months; in relapsed or refractory disease the complete-response rate was lower, near 16%, with a median duration of response around nine months. Notably, Decnupaz can be initiated in the outpatient setting, which for an ultra-rare disease with scattered, often older patients is a meaningful access advantage over therapies that require inpatient monitoring.

Where small molecules still fit: BCL-2 and FLT3

A surface receptor like CD123 is a job for an antibody, but BPDCN also has a soft spot that a small molecule hits hard. Primary BPDCN cells are dependent on the anti-apoptotic protein BCL-2 and are uniformly sensitive to the BCL-2 inhibitor venetoclax, a result first shown by BH3 profiling and since borne out by responses to venetoclax-containing regimens in the clinic. A subset of cases also carry FLT3 alterations, putting another well-characterized kinase pocket on the table. Those two — BCL-2 and FLT3 — are exactly the kind of deep, well-defined binding sites where structure-based design and docking are useful, in contrast to the flat surface of CD123.

Dock the small-molecule side yourself

Pivekimab is a biologic, but the small-molecule frontier in BPDCN runs through targets Liganx already carries. Liganx brings molecular docking online to the browser, so you can explore the druggable pockets that sit alongside the CD123 antibody strategy. Open Studio and dock a BH3-mimetic against BCL-2, or a kinase inhibitor against FLT3, to see how a small molecule engages a real pocket. If you want the BCL-2 background first, read our BCL-2 inhibitor deep-dive. Running the molecular docking next to the clinical picture is a fast way to see why some BPDCN targets are antibody problems and others are pocket problems.

Primary sources

• U.S. Food and Drug Administration. FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy. (May 27, 2026). fda.gov
• Montero J, Stephansky J, Cai T, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer Discov 7, 156–164 (2017). doi:10.1158/2159-8290.CD-16-0999
• Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med 380, 1628–1637 (2019). doi:10.1056/NEJMoa1815105